Theravance Biopharma, Inc. (NASDAQ: TBPH), an Ireland-based company that focuses on the discovery, development, and commercialisation of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system, announced on Tuesday that it has named Jim Kelly, as its new director.

Presently, Kelly is the managing director of Weiss Asset Management and a member of the firm's Investment Committee. He has around 20 years of experience as a professional investor in the public and private markets and a decade of experience investing in healthcare. He has served as an analyst at Farallon Capital Management, Madison Dearborn Partners and Lehman Brothers.

Rick E Winningham, chairman and CEO, said, 'We are pleased to welcome Jim Kelly to the Theravance board of directors. Weiss Asset Management has been one of our largest shareholders since 2021, and Jim has extensive investment experience as well as a thorough understanding of our industry, our company and the communities we serve. We believe Jim's perspective, knowledge of the capital markets and deep financial acumen are highly valuable to, and further strengthen, our board as we continue to execute on our strategy and seek to maximise value for all of our shareholders.'